Osmotica Subsidiary RVL Pharmaceuticals, Focused on Eye Care and Ocular Aesthetics, Strengthens and Expands Leadership Team
June 30, 2021 07:15 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, NJ, June 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that J....
Osmotica Pharmaceuticals plc Announces Conclusion of Strategic Process with Agreement for the Sale of Legacy Business to Alora Pharmaceuticals, LLC
June 25, 2021 06:50 ET
|
Osmotica Holdings US LLC
Osmotica will receive a $110 million upfront cash payment, with the potential to receive up to $60 million in additional milestone paymentsAlora will acquire manufacturing operations in Marietta,...
Osmotica Pharmaceuticals plc Announces Result of Proposal 3 at Annual General Meeting
June 18, 2021 06:50 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., June 18, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced results...
Osmotica Pharmaceuticals plc to Present at Jefferies Virtual Healthcare Conference 2021
May 25, 2021 17:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 25, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
Osmotica Pharmaceuticals plc Reports First Quarter 2021 Results and Provides Business Update
May 13, 2021 16:05 ET
|
Osmotica Holdings US LLC
First quarter 2021 total revenue of $23.9 million RVL Pharmaceuticals’ Upneeq wins 2021 MedTech Breakthrough Award; gainsrecognition as outstanding health and medical technology product Upneeq sales...
Osmotica Pharmaceuticals plc to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
May 12, 2021 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that...
RVL Pharmaceuticals Upneeq® Wins 2021 MedTech Breakthrough Award
May 10, 2021 08:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 10, 2021 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals, Inc., a subsidiary of Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”), a fully integrated biopharmaceutical company,...
Osmotica Pharmaceuticals plc to Provide First Quarter 2021 Business and Financial Update on May 13, 2021
May 07, 2021 16:05 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., May 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that the...
Osmotica Pharmaceuticals plc Reports Fourth Quarter and Full Year 2020 Results and Provides Business Update
March 30, 2021 16:05 ET
|
Osmotica Holdings US LLC
Fourth quarter and full year 2020 total revenue of $34.5 million and $177.9 million, respectively Received FDA approval and subsequently introduced Upneeq® (oxymetazoline hydrochloride ophthalmic...
Osmotica Pharmaceuticals plc to Provide Fourth Quarter and Full Year 2020 Business and Financial Update on March 30, 2021
March 24, 2021 16:30 ET
|
Osmotica Holdings US LLC
BRIDGEWATER, N.J., March 24, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, today announced that...